What is the catalog number for Edoxaban-d6?

The catalog number for Edoxaban-d6 is HY-10264S.

What sizes are available for Edoxaban-d6?

Edoxaban-d6 is available in the following size(s): 1 mg.

Is Edoxaban-d6 in stock?

Edoxaban-d6 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Edoxaban-d6?

Edoxaban-d6 is manufactured by QuantiMol.

What is the estimated delivery time for Edoxaban-d6?

Estimated delivery time for Edoxaban-d6 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Edoxaban-d6?

The safety data sheet for Edoxaban-d6 is available here: http://file.medchemexpress.com/batch_PDF/HY-10264S/Edoxaban-d6-SDS-MedChemExpress.pdf.

Edoxaban-d6

Edoxaban-d6 is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment[1][2][3].

Product Specifications

CAS Number

1304701-57-2

Product Name Alternative

DU-176-d6

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

Factor Xa; Thrombin

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.6

Solubility

10 mM in DMSO

Smiles

O=C(C1=NC2=C(CN(CC2)C)S1)N[C@H]3[C@H](CC[C@@H](C3)C(N(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)NC(C(NC4=CC=C(C=N4)Cl)=O)=O

Molecular Formula

C24H24D6ClN7O4S

Molecular Weight

554.09

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Furugohri T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6 (9) :1542-9.|[3]Mendell J, Lee F, Chen S, The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J Cardiovasc Pharmacol. 2013 Apr 23. [Epub ahead of print]|[4]Stacy ZA, et al. Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5 (1) :1-18.